Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylfentanyl refers to a group of synthetic opioid analgesics structurally related to fentanyl. The most well-known isomers are 3-methylfentanyl and alpha-methylfentanyl. These compounds act as potent agonists at the mu-opioid receptor and exhibit pharmacological effects similar to fentanyl but with significantly increased potency—3-methylfentanyl is estimated to be between 400–6000 times more potent than morphine. Methyl group substitution on the piperidine ring increases binding affinity for opioid receptors and can alter both potency and duration of action depending on the isomer. These drugs have no accepted medical use in most countries and are associated with high risk of fatal overdose due to respiratory depression. They have been encountered primarily as illicit substances mixed with or sold as heroin ("China White") or other opioids[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylfentanyl.